Genotype-phenotype Analysis of Paraoxonase 1 in Schizophrenic Patients Treated with Atypical Antipsychotics
1
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Objective: Recent studies suggest a possible involvement of low paraoxonase 1 (PON1) enzyme activities in the association between schizophrenia, treatment with atypical antipsychotics and increased cardiovascular (CVD) risk. In the present study, we aimed at investigating the PON1 status in a group of schizophrenic patients treated with either olanzapine or other antipsychotic, as compared to a group of healthy control participants. Methods: We assessed the arylesterase (AREase) and paraoxonase (POase) activities of PON1, as well as three common polymorphisms of PON1 gene (Q192R, L55M, −108C＞T). Results: We found significantly lower (−13.3%) AREase activity in schizophrenic patients, along with significantly lower (−18.2%) POase activity in olanzapine-treated patients with QQ genotype. Furthermore, we found a significant difference between groups in L55M polymorphism distribution, whereas Q192R and −108C＞T polymorphisms distributions were similar. Conclusion: We identified the olanzapine-treated patients with QQ genotype as having the lowest PON1 (POase) activity, providing a possible way of identifying schizophrenic patients exposed to the greatest risk of CVD.
Abstract
Objective: Recent studies suggest a possible involvement of low paraoxonase 1 (PON1) enzyme activities in the association between schizophrenia, treatment with atypical antipsychotics and increased cardiovascular (CVD) risk. In the present study, we aimed at investigating the PON1 status in a group of schizophrenic patients treated with either olanzapine or other antipsychotic, as compared to a group of healthy control participants. Methods: We assessed the arylesterase (AREase) and paraoxonase (POase) activities of PON1, as well as three common polymorphisms of PON1 gene (Q192R, L55M, −108C＞T). Results: We found significantly lower (−13.3%) AREase activity in schizophrenic patients, along with significantly lower (−18.2%) POase activity in olanzapine-treated patients with QQ genotype. Furthermore, we found a significant difference between groups in L55M polymorphism distribution, whereas Q192R and −108C＞T polymorphisms distributions were similar. Conclusion: We identified the olanzapine-treated patients with QQ genotype as having the lowest PON1 (POase) activity, providing a possible way of identifying schizophrenic patients exposed to the greatest risk of CVD.
참고문헌 (27)
- Bruijnzeel D, "Antipsychotic treatment of schizophrenia: an update", Asian J Psychiatr, 11, pp.3~7 (2014)[DOI]
- Haro JM, "The SOHO (Schizophrenia Outpatient Health Outcome) study: implications for the treatment of schizophrenia", CNS Drugs, 20, pp.293~301 (2006)[DOI]
- Yogaratnam J, "Metabolic complications of schizophrenia and antipsychotic medications--an updated review", East Asian Arch Psychiatry, 23, pp.21~28 (2013)
- Sarandol A, "Coronary artery disease risk factors in patients with schizophrenia: effects of short term antipsychotic treatment", J Psychopharmacol, 21, pp.857~863 (2007)[DOI]
- Janicak PG, "Schizophrenia: recent advances in diagnosis and treatment", pp.239~240 (2014), Springer
- Hennekens CH, "Schizophrenia and increased risks of cardiovascular disease", Am Heart J, 150, pp.1115~1121 (2005)[DOI]
- Costa LG, "Modulation of paraoxonase (PON1) activity", Biochem Pharmacol, 69, pp.541~550 (2005)[DOI]
- Gan KN, "Purification of human serum paraoxonase", arylesterase. Evidence for one esterase catalyzing both activities, 1991, pp.19, 100~106
- Chen J, "Haplotype-phenotype relationships of paraoxonase-1", Cancer Epidemiol Biomarkers Prev, 14, pp.731~734 (2005)[DOI]
- Mackness M, "Human paraoxonase-1 (PON1): Gene structure and expression, promiscuous activities and multiple physiological roles", Gene, 567, pp.12~21 (2015)[DOI]
- Mackness B, "Serum paraoxonase (PON1) 55 and 192 polymorphism and paraoxonase activity and concentration in non-insulin dependent diabetes mellitus", Atherosclerosis, 139, pp.341~349 (1998)[DOI]
- Richter RJ, "Determination of paraoxonase 1 status without the use of toxic organophosphate substrates", Circ Cardiovasc Genet, 1, pp.147~152 (2008)[DOI]
- Garin MC, "Paraoxonase polymorphism Met-Leu54 is associated with modified serum concentrations of the enzyme. A possible link between the paraoxonase gene and increased risk of cardiovascular disease in diabetes", J Clin Invest, 99, pp.62~66 (1997)[DOI]
- Precourt LP, "The three-gene paraoxonase family: physiologic roles, actions and regulation", Atherosclerosis, 214, pp.20~36 (2011)[DOI]
- Gupta N, "Paraoxonase 1 (PON1) polymorphisms, haplotypes and activity in predicting CAD risk in North-West Indian Punjabis", PLoS One, 6, pp.e17805~ (2011)[DOI]
- Unsal C, "Reduced serum paraoxonase 1 (PON1) activity in patients with schizophrenia treated with olanzapine but not quetiapine", Neuropsychiatr Dis Treat, 9, pp.1545~1552 (2013)
- Noto C, "Oxidative stress in drug naive first episode psychosis and antioxidant effects of risperidone", J Psychiatr Res, 68, pp.210~216 (2015)[DOI]
- Camkurt MA, "Serum paraoxonase levels of schizophrenia patients treated with typical, atypical and combined antipsychotics", Bull Clin Psychopharmacol, 25(Suppl 1), pp.S110~ (2015)
- American Psychiatric Association, "Diagnostic and statistical manual of mental disorders: DSM-5" (2013), American Psychiatric Publishing
- Brophy VH, "Effects of 5' regulatory-region polymorphisms on paraoxonase-gene (PON1) expression", Am J Hum Genet, 68, pp.1428~1436 (2001)[DOI]
- Eckerson HW, "The human serum paraoxonase", arylesterase polymorphism, 1983, pp.35, 1126~1138
- La Du BN, "Pharmacogenetics of drug metabolism", pp.51~91 (1992), Pergamon Press
- Mackness B, "Effect of the molecular polymorphisms of human paraoxonase (PON1) on the rate of hydrolysis of paraoxon", Br J Pharmacol, 122, pp.265~268 (1997)[DOI]
- Kucukali CI, "Paraoxonase-1 55", 192 genotypes in schizophrenic patients and their relatives in Turkish population, 2008, pp.18, 289~294
- Deakin SP, "Genetic and environmental factors modulating serum concentrations and activities of the antioxidant enzyme paraoxonase-1", Clin Sci (Lond), 107, pp.435~447 (2004)[DOI]
- Melkersson K, "Adverse metabolic effects associated with atypical antipsychotics: literature review and clinical implications", Drugs, 64, pp.701~723 (2004)[DOI]
- Andreasen NC, "Antipsychotic dose equivalents and dose-years: a standardized method for comparing exposure to different drugs", Biol Psychiatry, 67, pp.255~262 (2010)[DOI]